STOCK TITAN

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences earnings
Rhea-AI Summary
Revolution Medicines, Inc. will report financial results for the third quarter 2023 on November 6, 2023, after market close. The senior management team will host a webcast to discuss the financial results and provide an update on corporate progress. A replay will be available on the company's website for at least 14 days.
Positive
  • None.
Negative
  • None.

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2023 on Monday, November 6, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-5127 (KRASG12V), RMC-0708 (KRASQ61H) and RMC-8839 (KRASG13C) which are currently in IND-enabling development, and additional compounds targeting other RAS variants.


Revolution Medicines, Inc. will report its financial results for the third quarter 2023 on November 6, 2023, after market close.

During the webcast, Revolution Medicines, Inc.'s senior management team will discuss the financial results for the quarter and provide an update on corporate progress.

You can access the live webcast and the archived webcast of Revolution Medicines, Inc.'s financial results on the company's website: https://ir.revmed.com/events-and-presentations.

The replay of the webcast will be available on Revolution Medicines, Inc.'s website for at least 14 days.
Revolution Medicines Inc

NASDAQ:RVMD

RVMD Rankings

RVMD Latest News

RVMD Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Redwood City

About RVMD

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.